To assess benefits of Advagraf and Prograf in patients with different CYP3A5 genotypes after kidney transplantation

Trial Profile

To assess benefits of Advagraf and Prograf in patients with different CYP3A5 genotypes after kidney transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 01 Apr 2017 Results published in the Biomedicine and Pharmacotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top